Figure 6.

Peripherally restricted CB₁R antagonism restores liver function and cholesterol homeostasis in obese Magel2-null mice. Both JD5037 and SLV319 (3 mg/kg/day for 28 d) treatment reduced the HFD-induced hepatic injury and steatosis in obese Magel2-null mice, as manifested by the reduced serum levels of ALT (A, B), AST (C, D), and TG content in the liver (E, F). Both compounds were equally potent in normalizing serum cholesterol levels (G, H), but not in restoring the HDL/LDL cholesterol ratio in Magel2-null mice (I, J). Similar patterns of results were obtained both in obese male (left panels) and female (right panels) mice. Legend: Vehicle, V; JD5037, J; SLV319, S. Data represent the mean ± SEM from 5 to 10 mice per group. *P < 0.05 relative to STD-V of the same genotype; ^#P < 0.05 relative to HFD-V of the same genotype.